BRPI0608387A2 - compostos para o tratamento de doenças inflamatórias - Google Patents

compostos para o tratamento de doenças inflamatórias

Info

Publication number
BRPI0608387A2
BRPI0608387A2 BRPI0608387-0A BRPI0608387A BRPI0608387A2 BR PI0608387 A2 BRPI0608387 A2 BR PI0608387A2 BR PI0608387 A BRPI0608387 A BR PI0608387A BR PI0608387 A2 BRPI0608387 A2 BR PI0608387A2
Authority
BR
Brazil
Prior art keywords
compounds
treatment
disease
inflammatory diseases
well
Prior art date
Application number
BRPI0608387-0A
Other languages
English (en)
Inventor
Pascale Pouzet
Christoph Hoenke
Peter Nickolaus
Domnic Martyres
Birgit Jung
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0608387A2 publication Critical patent/BRPI0608387A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTOS PARA O TRATAMENTO DE DOENçAS INFLAMATóRIAS. A presente invenção refere-se às novas dihidrotienopirimidinas da fórmula 1, bem como aos sais farmacologicamente toleráveis, diastereómeros, enantiómeros, racematos, hidratos ou solvatos dos mesmos; que são apropriadas para o tratamento de dores ou doenças das vias respiratórias ou gastrointestinais, doenças inflamatórias das articulações, da pele ou dos olhos, doenças do sistema nervoso periférico ou central ou doenças de câncer, bem como composições farmacêuticas, que contêm esses compostos.
BRPI0608387-0A 2006-04-19 2006-04-19 compostos para o tratamento de doenças inflamatórias BRPI0608387A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2006/061680 WO2006111549A1 (de) 2005-04-21 2006-04-19 Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE102005019201A DE102005019201A1 (de) 2006-04-19 2006-04-19 Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen

Publications (1)

Publication Number Publication Date
BRPI0608387A2 true BRPI0608387A2 (pt) 2009-12-29

Family

ID=36678631

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608387-0A BRPI0608387A2 (pt) 2006-04-19 2006-04-19 compostos para o tratamento de doenças inflamatórias

Country Status (28)

Country Link
US (3) US7511045B2 (pt)
EP (2) EP1874781B9 (pt)
JP (1) JP5021624B2 (pt)
KR (1) KR101335964B1 (pt)
CN (1) CN101163706A (pt)
AR (1) AR053235A1 (pt)
AT (1) ATE434620T1 (pt)
AU (1) AU2006237354B2 (pt)
BR (1) BRPI0608387A2 (pt)
CA (1) CA2605161A1 (pt)
CY (1) CY1109348T1 (pt)
DE (2) DE102005019201A1 (pt)
DK (1) DK1874781T3 (pt)
EA (1) EA013108B1 (pt)
ES (1) ES2328400T3 (pt)
HR (1) HRP20090395T1 (pt)
IL (1) IL186749A (pt)
MX (1) MX2007012313A (pt)
NO (1) NO20074615L (pt)
NZ (1) NZ563488A (pt)
PL (1) PL1874781T3 (pt)
PT (1) PT1874781E (pt)
RS (1) RS51163B (pt)
SI (1) SI1874781T1 (pt)
TW (1) TWI380984B (pt)
UA (1) UA93872C2 (pt)
WO (1) WO2006111549A1 (pt)
ZA (1) ZA200707591B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
MX2010003826A (es) * 2007-10-18 2010-04-21 Boehringer Ingelheim Int Preparacion de dihidrotieno [3,2-d] pirimidinas e intermedios usados en la misma.
CN104069112A (zh) 2007-10-19 2014-10-01 贝林格尔.英格海姆国际有限公司 取代的哌啶子基-二氢噻吩并嘧啶
CA2702518A1 (en) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
CA2702524A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
WO2009053268A1 (de) * 2007-10-19 2009-04-30 Boehringer Ingelheim International Gmbh Neue phenyl-substituierte piperazino-dihydrothienopyrimidine
CA2705411A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
KR101244517B1 (ko) 2008-01-11 2013-03-18 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
SI2315755T1 (sl) * 2008-05-13 2012-10-30 Boehringer Ingelheim Int Sinteza dihidrotieno(3,2-d)pirimidindiolov in podobnih pirimidindiolov
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
CN102264705A (zh) * 2008-12-24 2011-11-30 辛根塔有限公司 制备芳基酰胺的方法
CA2753604A1 (en) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
CA2753597A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
WO2010104194A1 (en) * 2009-03-10 2010-09-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20140113877A1 (en) * 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
WO2013019966A1 (en) * 2011-08-04 2013-02-07 Allergan, Inc. Aromatic bycyclic derivatives as cxcr4 receptor modulators
US9206195B2 (en) * 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
GB201203266D0 (en) * 2012-02-24 2012-04-11 Randox Lab Ltd Assay for the detection of the phenylpiperazine family
WO2014105958A2 (en) 2012-12-26 2014-07-03 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
WO2014117947A1 (en) * 2013-02-04 2014-08-07 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
CN108299400B (zh) 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN103893183B (zh) * 2014-03-12 2016-02-10 中山大学 1-（2-氯苯基）-4-{噻吩并[3,2-d]嘧啶-4-基}哌嗪化合物在制备抗HIV-1病毒药物中应用
US9873702B2 (en) * 2014-12-05 2018-01-23 Southern Research Institute Heterocyclic compounds as biogenic amine transport modulators
WO2019045824A1 (en) * 2017-09-01 2019-03-07 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
CN111108109A (zh) 2017-09-20 2020-05-05 利奥制药有限公司 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
HRP20251042T1 (hr) 2017-10-23 2025-10-24 Boehringer Ingelheim International Gmbh Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild)
US11299497B2 (en) 2017-12-15 2022-04-12 UNION therapeutics A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
DK3724196T3 (da) 2017-12-15 2023-01-16 Union Therapeutics As Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
JP7198820B2 (ja) 2017-12-15 2023-01-04 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
CA3236757A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CA3234847A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2025518257A (ja) * 2022-06-02 2025-06-12 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｐｄｅ４ｂ阻害剤及びその用途
KR20250046278A (ko) * 2022-08-09 2025-04-02 시젱 하이스코 파마수티칼 씨오., 엘티디. Pde4b 억제제 및 이의 용도
EP4593838A1 (en) 2022-09-28 2025-08-06 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
JP2025534418A (ja) 2022-09-29 2025-10-15 蘇州愛科百発生物医薬技術有限公司 含窒素縮合複素環化合物、その調製方法、および医薬におけるその使用
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
JP2026514091A (ja) 2023-04-13 2026-05-01 上海壹迪生物技術有限公司 置換ジヒドロチエノピリミジン系化合物、その製造方法及び使用
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
CN121889398A (zh) * 2023-09-25 2026-04-17 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
WO2025161532A1 (zh) * 2024-02-01 2025-08-07 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025162431A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂化合物的口服药物组合物及其制备方法
WO2025162289A2 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂的晶型及其在医药上的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) * 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (pt) * 1963-06-17
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE663693A (pt) 1965-03-31
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE2032687A1 (en) * 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
DE1940572A1 (de) * 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (pt) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) * 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
RO62428A (fr) * 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4265738A (en) * 1979-10-25 1981-05-05 Goncharov Evgeny S Cleaning and/or grading machine for free-flowing materials
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
US6339089B2 (en) * 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
DE50103666D1 (de) 2000-10-12 2004-10-21 Boehringer Ingelheim Pharma Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE10064994A1 (de) * 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
US6587548B2 (en) * 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
EA008596B1 (ru) * 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) * 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶

Also Published As

Publication number Publication date
CA2605161A1 (en) 2006-10-26
EA200702200A1 (ru) 2008-04-28
WO2006111549A1 (de) 2006-10-26
CY1109348T1 (el) 2014-07-02
ES2328400T3 (es) 2009-11-12
DK1874781T3 (da) 2009-11-02
PL1874781T3 (pl) 2009-12-31
PT1874781E (pt) 2009-07-27
RS51163B (sr) 2010-10-31
JP2008536890A (ja) 2008-09-11
CN101163706A (zh) 2008-04-16
EP2060575A1 (de) 2009-05-20
JP5021624B2 (ja) 2012-09-12
DE502006004066D1 (de) 2009-08-06
MX2007012313A (es) 2007-11-21
DE102005019201A1 (de) 2006-11-02
IL186749A0 (en) 2008-02-09
UA93872C2 (ru) 2011-03-25
NO20074615L (no) 2007-11-19
SI1874781T1 (sl) 2009-12-31
EP1874781A1 (de) 2008-01-09
KR20080004621A (ko) 2008-01-09
AU2006237354B2 (en) 2012-03-01
NZ563488A (en) 2010-04-30
IL186749A (en) 2014-08-31
HRP20090395T1 (hr) 2009-08-31
TWI380984B (zh) 2013-01-01
ZA200707591B (en) 2009-08-26
AU2006237354A1 (en) 2006-10-26
US20100197656A1 (en) 2010-08-05
US7723341B2 (en) 2010-05-25
US20070259846A1 (en) 2007-11-08
EA013108B1 (ru) 2010-02-26
EP1874781B1 (de) 2009-06-24
AR053235A1 (es) 2007-04-25
US7511045B2 (en) 2009-03-31
US8354531B2 (en) 2013-01-15
ATE434620T1 (de) 2009-07-15
EP1874781B9 (de) 2010-09-08
US20090186875A1 (en) 2009-07-23
KR101335964B1 (ko) 2013-12-04

Similar Documents

Publication Publication Date Title
EA200702200A1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
ECSP10010156A (es) Piperidino-dihidrotienopirimidinas sustituidas
EA200802051A1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
BR122013028005B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
EA201200318A1 (ru) Гетероциклические оксимы
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
EA201200260A1 (ru) Гетероциклические гидразоны и их применение для лечения рака и воспаления
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
GT200900333A (es) Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.
BR112012006387A2 (pt) aminas de triazol fundidas como moduladores de p2x7
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
UY31682A1 (es) Compuestos derivados de azetetidinas, su preparacion y su aplicacion en terapeutica
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
BRPI0516626A (pt) pteridinas substituìdas e uso das mesmas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.